ESMC
Escalon Medical Corp.0.1400
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.04MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Escalon Medical posted Q2 revenue of $3.6M, up 11.5% y/y from $3.2M, driven by Sonomed product gains that offset Trek declines, while foreign sales hit 51.9%. Gross margin slipped to 56.7% from 51.1% on product mix shifts, flipping to $99K operating income from $256K yet yielding just $(0.02) YTD EPS loss on 7.4M shares due to preferred dividends. Cash drained to $337K after repaying TD Bank debt, with $(432K) operating cash flow; free cash flow not disclosed in the 10-Q. New NY lease adds future expenses. Cash burn persists. AXIS asset sale to Optos closed post-quarter for $3M. Tariffs threaten supply costs.
8-K
AXIS assets sold to Optos
Escalon Medical sold its AXIS platform software assets to Optos for $3M on January 23, 2026, pocketing the first $1M milestone after a $25K term-sheet advance. Remaining $2M hinges on tech transfer and integration milestones. Cash swells; pro forma gain hits $2.8M. Future payments remain conditional.
10-Q
Q1 FY2026 results
Escalon's Q1 FY2026 net revenues dipped 3.8% y/y to $2.7M, with products down 4.3% to $2.5M but service plans up 6.2%; gross margin slipped to 58.1% from 56.4% on product mix shifts (derived). Operating loss widened to $203K from $27K, driven by R&D jumping 53% to $216K for ultrasound and AXIS work, while MG&A edged up 0.7%. Cash flow strengthened sharply, generating $85K from operations minus $4K capex for $81K FCF (derived), lifting cash to $616K; TD note repaid post-quarter. EPS holds at -$0.03 on 7.4M shares, consistent. One customer drove 17% of sales. Tariffs threaten supply costs.
10-K
FY2025 results
Escalon Medical eked out a slim FY2025 profit of $105,525 on $12.0M revenue, up 0.5% y/y, with Trek products driving the gain while Sonomed and AXIS dipped slightly; gross margins expanded to 54.3% from 57.0% via product mix shifts, though R&D climbed 9.4% on AXIS consulting. Q4 momentum stayed steady, flipping from FY2024's $125K loss amid positive operating cash flow of $381K—yet inventory swelled $486K, signaling caution. Debt ticked down to $523K with $40K repayments, but liquidity strains persist alongside tariff uncertainties. Going concern doubts loom large.
10-Q
Q3 FY2025 results
Escalon Medical Corp. swung to profitability in Q3 FY2025 ended March 31, 2025, with net revenues climbing 28.9% y/y to $3.5M, driven by stronger sales of Sonomed's ultrasound products and Trek's gas products, while gross margin expanded to 46.1% from 41.4% on favorable product mix and geographic shifts. For the nine-month YTD, revenues rose 11.4% y/y to $9.5M, yielding operating income of $505K versus a $243K loss last year, and net income of $485K; diluted EPS held at $0.03 on 14.2M shares, reflecting preferred stock conversion effects with no anti-dilution from options. Cash swelled to $541K from $209K at FY start, bolstered by $365K operating cash flow—exceeding capex of zero for positive FCF—while total debt eased to $516K including a $133K TD note at 9.49% maturing 2028 and $143K EIDL at 3.75% over 30 years, with no revolver. Domestic sales edged to 55% of total, up from 52%, yet one customer tied to 16% of YTD revenue underscores concentration risks.
IPO
Employees
Sector
Industry
APYX
Apyx Medical Corporation
3.72-0.07
BSX
Boston Scientific Corporation
92.95+0.76
CNMD
CONMED Corporation
39.20-1.12
EW
Edwards Lifesciences Corporatio
85.32+1.94
GKOS
Glaukos Corporation
113.76+2.03
IRIX
IRIDEX Corporation
1.00+0.02
MASI
Masimo Corporation
134.52-2.88
RMD
ResMed Inc.
247.34-5.73
SGHT
Sight Sciences, Inc.
8.39+0.08
VYCO
Vycor Medical, Inc.
0.16+0.00